495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818609063147077632 |
|---|---|
| author | Geoffrey Gibney Ari VanderWalde Joanne Xiu Joseph Drabick Gino In Steven O’Day Kelsey Poorman W Korn |
| author_facet | Geoffrey Gibney Ari VanderWalde Joanne Xiu Joseph Drabick Gino In Steven O’Day Kelsey Poorman W Korn |
| author_sort | Geoffrey Gibney |
| collection | DOAJ |
| first_indexed | 2024-12-16T14:52:35Z |
| format | Article |
| id | doaj.art-25ea86b76a7443538df69b5b1ae74b2f |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-16T14:52:35Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-25ea86b76a7443538df69b5b1ae74b2f2022-12-21T22:27:33ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0495495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignanciesGeoffrey Gibney0Ari VanderWalde1Joanne Xiu2Joseph Drabick3Gino In4Steven O’Day5Kelsey Poorman6W Korn7Aff598 grid.213910.80000000119551644Lombardi Comprehensive Cancer Center Washington DC USA Aff6 grid.417886.40000000106575612Amgen Inc. Thousand Oaks CA USA Caris Life Sciences, Phoenix, Arizona, USAPenn State Cancer Institute, Hershey, Pennsylvania, USA3Norris Comprehensive Cancer Center, Los Angeles, CA, USA4John Wayne Cancer Institute, Santa Monica, CA, USA2Caris Life Sciences, Phoenix, AZ, USA2Caris Life Sciences, Phoenix, AZ, USA |
| spellingShingle | Geoffrey Gibney Ari VanderWalde Joanne Xiu Joseph Drabick Gino In Steven O’Day Kelsey Poorman W Korn 495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies Journal for ImmunoTherapy of Cancer |
| title | 495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies |
| title_full | 495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies |
| title_fullStr | 495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies |
| title_full_unstemmed | 495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies |
| title_short | 495 Basal cell carcinoma demonstrates a T-cell exclusion immune phenotype in contrast to other anti-PD-1 therapy responsive cutaneous malignancies |
| title_sort | 495 basal cell carcinoma demonstrates a t cell exclusion immune phenotype in contrast to other anti pd 1 therapy responsive cutaneous malignancies |
| work_keys_str_mv | AT geoffreygibney 495basalcellcarcinomademonstratesatcellexclusionimmunephenotypeincontrasttootherantipd1therapyresponsivecutaneousmalignancies AT arivanderwalde 495basalcellcarcinomademonstratesatcellexclusionimmunephenotypeincontrasttootherantipd1therapyresponsivecutaneousmalignancies AT joannexiu 495basalcellcarcinomademonstratesatcellexclusionimmunephenotypeincontrasttootherantipd1therapyresponsivecutaneousmalignancies AT josephdrabick 495basalcellcarcinomademonstratesatcellexclusionimmunephenotypeincontrasttootherantipd1therapyresponsivecutaneousmalignancies AT ginoin 495basalcellcarcinomademonstratesatcellexclusionimmunephenotypeincontrasttootherantipd1therapyresponsivecutaneousmalignancies AT stevenoday 495basalcellcarcinomademonstratesatcellexclusionimmunephenotypeincontrasttootherantipd1therapyresponsivecutaneousmalignancies AT kelseypoorman 495basalcellcarcinomademonstratesatcellexclusionimmunephenotypeincontrasttootherantipd1therapyresponsivecutaneousmalignancies AT wkorn 495basalcellcarcinomademonstratesatcellexclusionimmunephenotypeincontrasttootherantipd1therapyresponsivecutaneousmalignancies |